Company / Operating Income
Royalty Pharma plc Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$1.6B
FY2025
5-year range
$1.3B / $2.6B
FY2021-FY2025
Trend
+20.7%
vs FY2024
Sector context
#9 of 204
Health Care
What the data says
Among 204 Health Care companies, Royalty Pharma plc is in the top 4% for operating income. Operating Income returned to growth in FY2025 after 3 years of decline, reaching $1.6B.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 5-year CAGR of +2.7%. Top quartile in the Health Care sector.
Improved from $1.5B to $1.6B over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -0.8%
- 5-Year CAGR
- +2.7%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 204This company $1.6B Sector average $107.8M
▼
+1347.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +2.7%, indicating consistent growth.
- In FY2025, operating income increased 20.7% year-over-year.
- Ranks #9 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | +20.7% |
| FY2024 | $1.3B | -13.4% |
| FY2023 | $1.5B | -6.5% |
| FY2022 | $1.6B | -39.2% |
| FY2021 | $2.6B | +92.3% |
| FY2020 | $1.4B | -48.0% |
| FY2019 | $2.6B | +92.3% |
| FY2018 | $1.4B | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026